CI-1033 effectively inhibits the growth of esophageal squamous
cell carcinoma which co-expresses both EGFR and HER2 with
the inhibition of phosphorylation of both MAPK and AKT.CI-1033
was highly potent against EGFR (IC50 0.8 nM), HER-2(IC50 19
nM) and ErbB-4 (IC50 7 nM).
Claus Kamby. Cancer Treatment Reviews Volume 35, Issue 2, April
2009, Pages 121-136.Moasser, M.M. Current Opinion in Investigational
Drugs 2008 9 (12), pp. 1264-1276.Lecia V. Sequist. The Oncologist,
Vol. 12, No. 3, 325-330